SCHEMBL428928

SCHEMBL428928

CN(CC(=O)N1CCCCC1)C(=O)Cn1c(-c2ccc(OCc3ccccc3)cc2)c(-c2ccccc2)c2sc(C(=O)O)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 2/20 0.44
LTB4R Q15722 6/20 0.40
LTB4R2 Q9NPC1 5/20 0.40
NR4A2 P43354 1/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
TP53 P04637 1/20 0.36
RECQL P46063 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL428927 0.89 SMN1; SMN2 (0.41) SMN1; SMN2LMNALTB4RLTB4R2NR4A2
SCHEMBL424913 0.85 NR4A2 (0.46) LTB4RLTB4R2NR4A2EGFR
SCHEMBL2996607 0.82 ALDH1A1 (0.43) SMN1; SMN2LMNANR4A2ALDH1A1NPC1
Hydrochloric Acid SCHEMBL426991 0.81 EGFR (0.44) SMN1; SMN2NR4A2ALDH1A1NPC1RAB9A
SCHEMBL5732725 0.81 ACHE (0.43) SMN1; SMN2NR4A2ALDH1A1KMT2AHRH3
SCHEMBL426003 0.80 EGFR (0.46) LTB4RLTB4R2NR4A2EGFR
Hydrochloric Acid SCHEMBL425039 0.80 ACHE (0.43) SMN1; SMN2NR4A2ALDH1A1KMT2AHRH3
SCHEMBL428663 0.78 NR4A2 (0.51) NR4A2HRH3
SCHEMBL423858 0.77 NR4A2 (0.44) SMN1; SMN2NR4A2RAB9AKMT2AHRH3
SCHEMBL428489 0.77 NR4A2 (0.44) SMN1; SMN2LMNANR4A2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120020920-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-01-26 US claimed
US-20090036444-A1 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2009-02-05 US claimed
EP-1688420-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2006-08-09 EP claimed
US-20120020920-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-01-26 US disclosed
US-20090036444-A1 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2009-02-05 US disclosed
EP-1688420-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036444-A1 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor GTF3C5, ZC3HAV1, POLI SMN1; SMN2 4383/4885LMNA 4306/4885LTB4R 4189/4885
US-20120020920-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR GTF3C5, ZC3HAV1, POLI SMN1; SMN2 4383/4885LMNA 4306/4885LTB4R 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.